EP3134516A2 - Protéines vsv-g chimères utilisables en tant que véhicules de transfert d'acides nucléiques - Google Patents

Protéines vsv-g chimères utilisables en tant que véhicules de transfert d'acides nucléiques

Info

Publication number
EP3134516A2
EP3134516A2 EP15783023.3A EP15783023A EP3134516A2 EP 3134516 A2 EP3134516 A2 EP 3134516A2 EP 15783023 A EP15783023 A EP 15783023A EP 3134516 A2 EP3134516 A2 EP 3134516A2
Authority
EP
European Patent Office
Prior art keywords
seq
chimeric protein
vsv
nucleic acid
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15783023.3A
Other languages
German (de)
English (en)
Other versions
EP3134516A4 (fr
Inventor
Sujata ACHARJEE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2015/027496 external-priority patent/WO2015164726A2/fr
Publication of EP3134516A2 publication Critical patent/EP3134516A2/fr
Publication of EP3134516A4 publication Critical patent/EP3134516A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain

Definitions

  • a chimeric or fusion protein including a membrane transport domain and a nucleic acid binding domain allowing targeted delivery of nucleic acids in humans and animals for the treatment of medical conditions.
  • the vesicular stomatitis virus G glycoprotein (hereinafter referred to as
  • VSV-G is widely used to pseudotype viral vectors due to its wide tropism and stability. These viral vectors facilitate gene transduction in human and animals.
  • the VSV-G proteins when not associated with any viral vectors, are also alone capable of forming complexes with naked plasmid DNA in cell free conditions which can be transfected to cells thereafter.
  • VSV-G has been used as an efficient surrogate envelope protein to produce more stable and high titer pseudotyped murine leukemia virus (MLV)-based retrovirus and lentivirus-based vectors, all of which have been effectively used for gene therapy.
  • MLV murine leukemia virus
  • LDL low- density lipoprotein
  • VSV-G mutants have been generated which are more thermostable as well as serum-resistant. VSV-G mutants harboring T230N + T368A or K66T+ S162T + T230N + T368A mutations exhibited more resistance to serum inactivation and higher thermostability.
  • VSV-G can form a complex with naked plasmid DNA in the absence of any transfection reagent and can thereby enhance the transfection of naked plasmid DNA into cells.
  • Sucrose gradient sedimentation analysis demonstrated that VSV-G associates with plasmid DNA and MLV gag-pol particles to form ternary complexes that co- sediment with high DNA transfecting activity. This transfection could be abolished by adding antibody for VSV-G.
  • heritable genetic material is packaged into structures known as chromatin consisting of DNA and protein.
  • the basic repeating unit of chromatin is the nucleosome core, which consists of 147 base pairs of DNA wrapped in 1.7 left-handed superhelical turns around the surface of an octameric protein core formed by two molecules each of histones H2A, H2B, H3, and H4.
  • Histones are highly basic proteins that bind very avidly and non- specifically to nucleic acids. Histones were among the first proteins studied due to their relative ease of isolation and all four histone proteins (H2A, H2B, H3, and H4) can be expressed in bacteria.
  • SSBP Single Strand DNA-Binding Proteins
  • SSBP-1 is a housekeeping gene involved in mitochondrial biogenesis. It is also a subunit of a single-stranded DNA (ssDNA)-binding complex involved in the maintenance of genome stability.
  • Ribonuclease III (hereinafter referred to as "RNase III") is an enzyme that is expressed in most of the cells and is involved in the processing of pre-rRNA. It has a catalytic domain and an RNA binding domain that is located in the C-terminal end of the enzyme. Inhibition of human RNase III resulted in cell death suggesting a very important role of this enzyme.
  • Gene therapy and exon skipping have served as a means of gene transduction or gene manipulation respectively in humans during the past two decades. Gene therapy and exon skipping were initially developed as therapeutic strategies focused to address detrimental monogenetic diseases for which there were no available options for treatment, e.g. primary immunodeficiency. These approaches later found widespread application in curing neurodegenerative diseases, cancer, metabolic disorders, and more.
  • Gene therapy involves delivery of genes of interest cloned in viral vectors which are capable of producing viruses when transduced in human cells. Despite the continuous improvement of retroviral and lentiviral gene transfer systems for gene delivery during the last many years, there remain severe limitations preventing the development of efficient and safe clinical applications for these systems.
  • Exon skipping is a therapeutic strategy where antisense oligonucleotides
  • AO AO
  • VitraveneTM an intraocular injection to inhibit AO
  • AOs cytomegalovirus retinitis in immunocompromised patients; Isis Pharmaceuticals, Carlsbad, CA), and this drug is no longer marketed.
  • AOs include difficulty in achieving pharmacologically significant concentrations in cells due to biological barriers like endothelial and basement membrane, cell membrane, and sequestration by phagolysosomes.
  • a chimeric protein incorporating a transport domain and a nucleic acid binding domain and methods of utilizing those chimeric proteins for targeted delivery of therapeutic nucleic acids.
  • the present disclosure is directed to a chimeric protein comprising VSV-G and a nucleic acid binding protein.
  • the nucleic acid binding protein is a histone.
  • the histone is selected from the group consisting of: H2A, H2B, H3, and H4.
  • the histone is tagged with VSV-G at the C-terminus.
  • histone is tagged with VSV-G at the N-terminus.
  • the chimeric protein comprises SEQ. ID NO.: 1,
  • the chimeric protein comprises SEQ. ID NO.: 15, SEQ. ID NO.: 16, SEQ. ID NO.: 17, SEQ. ID NO.: 18, SEQ. ID NO.: 19, SEQ. ID NO.: 20, SEQ. ID NO.: 21, or SEQ. ID NO.: 22, and pharmacologically acceptable equivalents thereof.
  • the chimeric protein includes a sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ. ID NO.: 1, SEQ. ID NO.: 2, SEQ. ID NO.: 3, SEQ. ID NO.: 4, SEQ. ID NO.: 5, SEQ. ID NO.: 6, SEQ. ID NO.: 7, or SEQ. ID NO.: 8.
  • SEQ. ID NO.: 1 SEQ. ID NO.: 2
  • SEQ. ID NO.: 3 SEQ. ID NO. 4
  • SEQ. ID NO.: 5 SEQ. ID NO.: 6
  • SEQ. ID NO.: 7 SEQ. ID NO.: 8.
  • the chimeric protein includes a sequence having at least 90%>, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ. ID NO.: 15, SEQ. ID NO.: 16, SEQ. ID NO.: 17, SEQ. ID NO.: 18, SEQ. ID NO.: 19, SEQ. ID NO.: 20, SEQ. ID NO.: 21, or SEQ. ID NO.: 22.
  • the nucleic acid binding protein is SSBP-1.
  • SSBP-1 is tagged with VSV-G at the C-terminus.
  • SSBP-1 is tagged with VSV-G at the N-terminus.
  • the chimeric protein comprises SEQ. ID NO.: 9 or SEQ. ID NO.: 10, and pharmacologically acceptable equivalents thereof. In some embodiments, the chimeric protein comprises SEQ. ID NO.: 23 or SEQ. ID NO.: 24, and pharmacologically acceptable equivalents thereof. In some embodiments, the chimeric protein includes a sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ. ID NO.: 9 or SEQ. ID NO.: 10.
  • the chimeric protein includes a sequence having at least 90%>, at least 95%, at least 96%>, at least 97%, at least 98%, or at least 99% sequence identity with SEQ. ID NO.: 23 or SEQ. ID NO.: 24.
  • the nucleic acid binding protein is RNase III.
  • RNase III is tagged with VSV-G at the C-terminus.
  • RNase III is tagged with VSV-G at the N-terminus.
  • the chimeric protein comprises SEQ. ID NO.: 11, SEQ. ID NO.: 12, or SEQ. ID NO.:
  • the chimeric protein comprises SEQ. ID NO.: 14, SEQ. ID NO.: 25, or SEQ. ID NO.: 26, and pharmacologically acceptable equivalents thereof.
  • the chimeric protein includes a sequence having at least 90%, at least 95%, at least 96%>, at least 97%, at least 98%, or at least 99% sequence identity with SEQ. ID NO.: 11, SEQ. ID NO.: 12, or SEQ. ID NO.: 13.
  • the chimeric protein includes a sequence having at least 90%>, at least 95%, at least 96%>, at least 97%, at least 98%, or at least 99% sequence identity with SEQ. ID NO.: 14, SEQ. ID NO.: 25, or SEQ. ID NO.: 26.
  • the present disclosure is directed to a method of treating a medical condition in a subject comprising the steps of providing a therapeutic compound comprising a chimeric protein including VSV-G, a nucleic acid binding protein, and at least one nucleic acid, and administering to said subject a pharmaceutically active amount of said therapeutic compound.
  • the present disclosure is directed to a therapeutic compound comprising a chimeric protein as described herein.
  • FIG. 1 portrays chimeric VSV-G H2A protein fractions purified by SDS-
  • FIG. 2 portrays western blot analysis of the proteins in the purified fractions from SDS-PAGE analysis as seen in FIG. 1.
  • FIG. 3 portrays expression of GFP:HEK 293 cells trans fected with eGFPNl plasmid.
  • FIG. 4 A portrays GFP-including plasmid eGFPNltransfected in HEK293 cells using purified VSV-G-H2A protein.
  • FIG. 4B portrays GFP-including plasmid eGFPNl transfected in NIH 3T3 cells using purified VSV-G-H2A protein.
  • FIG. 5 portrays a method of treating a medical condition using a chimeric protein such as that isolated in FIG. 1.
  • the present disclosure is directed to a number of chimeric VSV-G (or VSV-G variants) proteins comprising VSV-G and at least one nucleic acid binding protein.
  • these proteins are used as transfer vehicles to enhance delivery of nucleic acids like plasmid DNA, single and double stranded DNA and RNA, and antisense oligonucleotides into human and animal cells.
  • VSV-G cloned in expression plasmids when transfected in cells, form sedimetable vesicles in the absence of any viral components.
  • the chimeric proteins described here efficiently complex with nucleic acids in cell free systems and can be used as an effective means for delivering AOs and genes of interest in human and animal cells. This approach mitigates a number of risks and issues that are associated with gene therapy and exon skipping, i.e. there is no risk of toxicity related to viral production or risk of viral genome incorporation and possible mutations arising as a result.
  • the transduction efficiency of the chimeric VSV-G-nucleic acid transfer vehicle is higher than that achieved by exon-skipping.
  • the chimeric VSV-G-nucleic acid transfer vehicle consistent with some embodiments of the present disclosure can also replace the current mechanism of gene therapy. As this proposed chimeric VSV-G-nucleic acid transfer vehicle does not rely on virus production, it has fewer side effects and can be administered subcutaneously. This system can be used for gene replacement and can have wide application to cure many disorders arising from genetic mutations. [0030]
  • wild-type VSV-G is used in the chimeric protein.
  • VSV-G variants are used in the chimeric protein.
  • the VSV-G variants include the thermostable and serum resistant mutants of VSV-G, e.g. S162T, T230N, T368A, or combined mutants T230N + T368A or K66T + S 162T +T230N + T368A.
  • variant VSV-G has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with wild- type VSV-G.
  • VSV-G refers to both wild-type VSV-G and VSV-G variants.
  • the chimeric protein of the present disclosure has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the combined sequence of VSV-G + nucleic acid binding protein, with the nucleic acid binding protein tagged with VSV-G at the C-terminus.
  • chimeric protein has at least 90%>, at least 95%, at least 96%>, at least 97%, at least 98%>, or at least 99% sequence identity with the combined sequence of VSV-G + nucleic acid binding protein, with the nucleic acid binding protein tagged with VSV-G at the N-terminus.
  • the chimeric protein comprises a nucleotide sequence that has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with at least one of SEQ. ID NO. : 1 , SEQ. ID NO. : 3, SEQ. ID NO.: 5, SEQ. ID NO.: 7, SEQ. ID NO.: 9, SEQ.
  • the chimeric protein comprises an amino acid sequence that has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with at least one of SEQ. ID NO.: 2, SEQ. ID NO.: 4, SEQ. ID NO.: 6, SEQ. ID NO.: 8, SEQ. ID NO.: 10, SEQ. ID NO.: 12, SEQ. ID NO.: 14, SEQ. ID NO.: 16, SEQ. ID NO.: 18, SEQ. ID NO.: 20, SEQ. ID NO.: 22, SEQ. ID NO.: 24, or SEQ. ID NO.: 26.
  • any suitable mutations is selected from any suitable mutations,
  • substitutions, additions, and deletions may be made to the chimeric protein so long as the pharmacological activity of the resulting variant chimeric protein is retained.
  • the nucleic acid binding protein is selected from the group consisting of H2A histone, H2B histone, H3 histone, H4 histone, SSBP-1, RNase III, and combinations thereof.
  • SEQ. ID NO: 1 is a nucleotide sequence of an H2A histone-VSV-G chimeric protein, with VSV-G at the C-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 2 is an amino acid sequence of an H2A histone-VSV-G chimeric protein, with VSV-G at the C-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 3 is a nucleotide sequence of an H2B histone-VSV-G chimeric protein, with VSV-G at the C-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 4 is an amino acid sequence of an H2B histone-VSV-G chimeric protein, with VSV-G at the C-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 5 is a nucleotide sequence of an H3 histone-VSV-G chimeric protein, with VSV-G at the C-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 6 is an amino acid sequence of an H3 histone-VSV-G chimeric protein, with VSV-G at the C-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 7 is a nucleotide sequence of an H4 histone-VSV-G chimeric protein, with VSV-G at the C-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 8 is an amino acid sequence of an H4 histone-VSV-G chimeric protein, with VSV-G at the C-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 9 is a nucleotide sequence of an SSBP-l-VSV-G chimeric protein, with VSV-G at the C-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 10 is an amino acid sequence of an SSBP-1- VSV-G chimeric protein, with VSV-G at the C-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 11 is a nucleotide sequence of an RNase III-VSV-G chimeric protein, with VSV-G at the C-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 12 is an amino acid sequence of an RNase III-VSV-G chimeric protein, with VSV-G at the C-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 13 is a nucleotide sequence of a partial RNase III-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 14 is an amino acid sequence of a partial RNase III-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 15 is a nucleotide sequence of an H2A histone-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 16 is an amino acid sequence of an H2A histone-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 17 is a nucleotide sequence of an H2B histone-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 18 is an amino acid sequence of an H2B histone-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 19 is a nucleotide sequence of an H3 histone-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 20 is an amino acid sequence of an H3 histone-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 21 is a nucleotide sequence of an H4 histone-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 22 is an amino acid sequence of an H4 histone-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 23 is a nucleotide sequence of an SSBP-l-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 24 is an amino acid sequence of an SSBP-l-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 25 is a nucleotide sequence of an RNase III-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • SEQ. ID NO: 26 is an amino acid sequence of an RNase III-VSV-G chimeric protein, with VSV-G at the N-terminus, consistent with some embodiments of the present disclosure.
  • the present disclosure is directed to a therapeutic compound comprising a chimeric protein consistent with those described in the above- identified embodiments.
  • the present disclosure is directed to a method of treating a medical condition within a subject.
  • the method of treating a subject comprises the steps of providing 500 a therapeutic compound comprising a chimeric protein including VSV-G, a nucleic acid binding protein, and at least one nucleic acid, and administering 510 to the subject a pharmaceutically active amount of the therapeutic compound.
  • at least one nucleic acid is a therapeutic gene.
  • VSV-G-H2A chimeric gene was synthesized using the propriety technology from Integrated DNA Technologies, Skokie, IL.
  • the VSV-G-H2A gene was cloned in the mammalian expression vector pTT5 at EcoRI and Notl restriction enzyme sites. The plasmid was prepared and sequenced for confirmation.
  • HEK293T cells were passed to -70% confluency a day prior to transfection
  • T75 flasks 3x T75 flasks, ⁇ 7.5xl0 6 cells/flask.
  • the cells in T75 flasks were transfected using Lipofectamine® 2000 (Life Technologies Corp., Carlsbad, CA) (per T75 flask: 3: 1 ratio; 20ug DNA; and 60 Lipofectamine® 2000). Flasks were incubated at 37°C and 5% C0 2 overnight. 24 hours after transfection, the conditioned media was removed and replaced with fresh media (14 mL/flask). Cells were further incubated overnight. Conditioned media was harvested and replaced with fresh media (14 mL/flask) and again incubated overnight.
  • Harvested media was then filtered using 0.45 ⁇ filter and stored at -80°C. The following day, conditioned media was harvested again and filtered using 0.45 ⁇ filter. Conditioned media was pooled with media from the previous day (-84 mL).
  • Conditioned media was centrifuged using the Optima® Ultra Centrifuge (with swinging bucket rotor SW32Ti) (Beckman Coulter, Inc., Brea, CA) at 25,000 rpm for 2h at 4°C (3 centrifuge tubes, -28 mL/tube). Supernatant was removed and pellets were resuspended in 5 mL PBS per tube. 5 mL of 20% sucrose/PBS cushion plus 5mL resuspended pellet was added to a new centrifuge tube. PBS was overlaid to fill the centrifuge tube. Samples were centrifuged at 25,000 rpm for 6 hours at 4°C.
  • Lane 1 Negative Control - untransfected cells only; Lane 2: molecular weight marker; Lane 3 : M20336-01 (20 load); Lane 4: M20336-01 (2 load); Lane 5 : molecular weight marker; and Lane 6: M20336-02 (20 ⁇ ⁇ load).
  • the HEK293 untransfected lane did not stain for any protein while rest of the lanes containing the fractions of purified VSV-G-H2A chimeric protein stained for proteins confirming the presence of purified proteins in the fractions.
  • proteins were run using the same conditions as described above and transferred to nitrocellulose membrane.
  • the chimeric VSV-G-H2A protein was detected by probing with anti-VSV-G-primary antibody and anti-rabbit HRP secondary antibody. Proteins were transferred to nitrocellulose membrane using Bio-Rad Trans-Blot® TurboTM. Signal was detected using the SNAP id® system (Merck KGAA, Darmstadt, DE) and
  • a band was detected specific to the size of VSV-G H2A chimeric protein at 75 kD in lanes 2 and 6 containing 20 ⁇ ⁇ load of protein. No bands were detected in lanes 4 and 8 with 2 ⁇ ⁇ load of purified protein fraction and non-transfected HEK293 protein fraction. Therefore, the presence of VSV-G-H2A chimeric protein in the purified fraction was confirmed. [0065] In order to evaluate the capacity of the purified VSV-G-H2A chimeric protein to act as nucleic acid transfer vehicle, HEK293 cells and NIH 3T3 cells were transfected with green fluorescent protein (GFP) expressing plasmid eGFPNl utilizing the VSV-G-H2A chimeric protein.
  • GFP green fluorescent protein
  • the eGFPNl plasmid was transfected in HEK293 cells using ViaFectTM trans fection reagent (Promega Corp., Madison, WI) to confirm that GFP was expressed properly. Successful GFP expression is shown in FIG. 3.
  • G-H2A chimeric protein was used as a transfer vehicle, 2 ⁇ g of eGFPNl plasmid was mixed with 3 ⁇ g of VSV-G H2A purified chimeric protein and overlaid in each of HEK293 and NIH 3T3 cells seeded on coverslips in 6-well plates. Cells were incubated for 48 hours before analysis. To detect whether GFP has expressed, the existing medium in the cells was aspirated, washed in Dulbecco's phosphate buffered saline (DPBS), and then fixed in 4% paraformaldehyde solution.
  • DPBS Dulbecco's phosphate buffered saline

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne la conception et la production d'un certain nombre de protéines VSV-G chimères (ou de variants de VSV-G) utilisées en tant que véhicules de transfert pour améliorer l'administration d'acides nucléiques tels que l'ADN plasmidique et l'ADN et l'ARN simple et double brin, ainsi que d'oligonucléotides antisens en direction de cellules humaines et animales. Ces véhicules de transfert protéines VSV-G chimères-acide nucléique peuvent être utilisés de multiples façons pour l'administration d'acides nucléiques, pour un saut d'exon et l'administration de gènes en vue du remplacement de gènes chez l'être humain et l'animal.
EP15783023.3A 2014-04-25 2015-04-24 Protéines vsv-g chimères utilisables en tant que véhicules de transfert d'acides nucléiques Withdrawn EP3134516A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984290P 2014-04-25 2014-04-25
PCT/US2015/027496 WO2015164726A2 (fr) 2014-04-25 2015-04-24 Protéines vsv-g chimères utilisables en tant que véhicules de transfert d'acides nucléiques

Publications (2)

Publication Number Publication Date
EP3134516A2 true EP3134516A2 (fr) 2017-03-01
EP3134516A4 EP3134516A4 (fr) 2017-12-13

Family

ID=57860012

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15783023.3A Withdrawn EP3134516A4 (fr) 2014-04-25 2015-04-24 Protéines vsv-g chimères utilisables en tant que véhicules de transfert d'acides nucléiques

Country Status (1)

Country Link
EP (1) EP3134516A4 (fr)

Also Published As

Publication number Publication date
EP3134516A4 (fr) 2017-12-13

Similar Documents

Publication Publication Date Title
US8569065B2 (en) Compositions and methods for the delivery of biologically active RNAs
AU2015338993B2 (en) RNA guided eradication of human JC virus and other polyomaviruses
US20190038770A1 (en) Rna guided eradication of human jc virus and other polyomaviruses
CN115175991A (zh) 工程化肌肉靶向组合物
KR20210102883A (ko) 알부민 좌위로부터 트랜스진을 발현하기 위한 조성물 및 방법
US20130164845A1 (en) Compositions and Methods for the Delivery of Biologically Active RNAs
WO2018057863A1 (fr) Silençage de dux4 par des complexes d'édition de gène recombinant
WO2016030501A1 (fr) Vecteurs synthétiques de rétrotransposon alu destinés à la thérapie génique
US9655979B2 (en) RNA trans-splicing molecule (RTM) for use in the treatment of cancer
Lu et al. CRISPR/Cas9 delivery strategies with engineered extracellular vesicles
US20180036429A1 (en) Chimeric vsv-g proteins as nucleic acid transfer vehicles
Shalaby et al. Development of non-viral vectors for neuronal-targeted delivery of CRISPR-Cas9 RNA-proteins as a therapeutic strategy for neurological disorders
US20230383275A1 (en) Sgrna targeting aqp1 rna, and vector and use thereof
EP3134516A2 (fr) Protéines vsv-g chimères utilisables en tant que véhicules de transfert d'acides nucléiques
US20230016983A1 (en) Antisense oligonucleotides and thier use for the treatment of cancer
US8722617B2 (en) Mussel adhesive protein derived vectors for gene delivery
US11566247B2 (en) Modulation of alternative MDM2 splicing
US20240189426A1 (en) Chimeric receptors targeting muc16 and uses thereof
Lockhart Design and Delivery of Synthetic mRNA by a Peptide Nanoparticle
Vaughan DNA trafficking in non-viral gene therapy: The role of the cytoskeleton
Miller Mechanism of nuclear import of a smooth muscle cell-specific plasmid vector for gene therapy
Johnson Comparative analysis of cellular proteins in stably and transiently produced lentiviral vectors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20161116

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20171109

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/145 20060101AFI20171103BHEP

Ipc: C12N 15/62 20060101ALI20171103BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180609